Citations 2
Interim Results From the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
Zolty, Ronald , Kingrey, J.F. , Penn, Benjamin G., Sobol, Irina , Sood, Namita , Benza, R.L., Channick, Richard N. , McLaughlin, Vallerie V. , Vachiéry, Jean‐Luc , Zamanian, R.T., Cravets, Matt , Roscigno, R.F., Mottola, David, Parsley, E., Aranda, R., Zisman, Lawrence S. , Investigators, on behalf of the TORREY Study, Sitbon, Olivier , Sahay, Sandeep , Subías, Pilar Escribano , Penn, B., Channick, Richard N. , Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , McLaughlin, Vallerie V. , Ghofrani, Hossein Ardeschir
A14. BUILDING LEGO(LAND): LESSONS LEARNED FROM LARGE SCALE CLINICAL TRIALS IN PAH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1011-A1011
Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial
McLaughlin, V.V., Zolty, Ronald , Channick, Richard N. , Chin, K. , Vachiéry, Jean‐Luc , Zamanian, R.T., Cravets, Matt , Roscigno, R.F., Mottola, David, Elman, Erin, Parsley, E., Aranda, R., Zisman, Lawrence S. , Investigators, on behalf of the TORREY Study, Frantz, Robert P. , Sahay, Sandeep , Subías, Pilar Escribano , Benza, Raymond L. , Channick, Richard N. , Hemnes, Anna R. , Howard, Luke , Sitbon, Olivier , Ghofrani, Hossein Ardeschir
D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A6726-A6726